B/ /642 CFW:



PATENT Attorney Docket No. LEX-007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

Gillies et al.

SERIAL NO.:

09/621,268

GROUP NO.:

1642

FILING DATE:

July 21, 2000

EXAMINER:

K. Canella

TITLE:

FC Fusion Proteins For Enhancing the Immunogenicity of Protein And

Peptide Antigens

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence, and any document(s) referred to as enclosed herein, are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 8th day of March, 2005.

Brenda L. MacLean


Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith are:

- 1. Transmittal Form (1 page);
- 2. Power of Attorney by Assignee of Entire Interest/Revocation of Prior Powers and New Power of Attorney (1 page);
- 3. and a return receipt postcard.

	OIPE						
1	[3]		Application	Serial Number	09/62	1,268	
MAR 1 0 2005 2			Filing Date		July 2	July 21, 2000	
			First Named	Inventor Gillies		3	
TRANSMITTAL			Group Art Unit		1642	1642	
			Examiner Name		K. Ca	K. Canella	
FORM			Attorney Docket No.		LEX-	LEX-007	
			Confirmatio	n No.	3473		
ENCLOSURES (check all that apply)							
☐ Fee	Transmittal Form		Copy of Notice Parts of Applic	e to File Missing cation		Notice of Appeal to Board of Patent Appeals and Interferences	
	☐ Check Attached ☐ Copy of Fee Transmittal Form		Formal Drawir	ng(s)		Appeal Brief (in triplicate)	
	Amendment/Response		Request For Co			Status Inquiry	
	☐ Preliminary ☐ After Final		Transmittal		\boxtimes	Return Receipt Postcard	
	☐ Affidavits/declaration(s) ☐ Letter to Official ☐ Draftsperson			· ·		Certificate of First Class Mailing under 37 C.F.R. 1.8 (1 page)	
	including Drawings [Total Sheets]		Terminal Discl			Certificate of Facsimile	
	Petition for Extension of Time		Executed Declaration and Power of Attorney for Utility or Design Patent Application			Transmission under 37 C.F.R. 1.8 Additional Enclosure(s) (please identify below)	
	Information Disclosure Statement		Small Entity Statement				
[Form PTO-1449 Copies of IDS Citations		CD(s) for large	e table or computer			
	Certified Copy of Priority Document(s)		Amendment After Allowance				
	Sequence Listing submission Paper Copy/CD Computer Readable Copy Statement verifying identity of above		Request for Certificate of Correction Certificate of Correction (in duplicate)				
CORRESPONDENCE ADDRESS				SIGNATURE BLO	OCK	Dognatfully submitted	
75 State Street Boston, MA 02109-1808				Date: March 8, 2005 Reg. No. 48,645 Tel. No.: (617) 261-3169 Fax No.: (617) 261-3175		Respectfully submitted, Brian A. Fairchild Attorney for Applicants Kirkpatrick & Lockhart Nicholson Graham LLP 75 State Street Boston, MA 02109-1808	





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INVENTORS:

Gillies et al.

ASSIGNEE:

EMD Lexigen Research Center Corp.

SERIAL NO.:

09/621,268

FILING DATE:

July 21, 2000

TITLE:

Fc Fusion Proteins for Enhancing the Immunogenicity of Protein and Peptide

Antigens

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST REVOCATION OF PRIOR POWERS AND NEW POWER OF ATTORNEY

Sir:

As an authorized representative of the assignee of record of the entire right, title, and interest in the above-identified patent application, I hereby revoke all powers of attorney previously given and hereby appoint the registered patent practitioners associated with Customer Number 022832 to prosecute and transact all business in the U.S. Patent and Trademark Office connected therewith.

Please direct all correspondence for the above-identified patent application to the address associated with the above Customer Number.

The assignee of record of the entire right, title, and interest in the above-identified patent application is EMD Lexigen Research Center Corp., by virtue of the chain of title from the inventors of the above-identified patent application to the current assignee, as shown below:

By assignment on February 28, 2002, from inventors Stephen D. Gillies, Kin-Ming Lo, and John Wesolowski to Lexigen Pharmaceuticals Corp., recorded in the United States Patent and Trademark Office on March 28, 2002, at Reel No. 012755, Frame No. 0449; and

By change of corporate name from Lexigen Pharmaceuticals Corp. to EMD Lexigen Research Center Corp., on May 30, 2002, recorded in the United States Patent and Trademark Office on December 19, 2003, at Reel No. 014815, Frame No. 0751.

Respectfully submitted,

Dated: $\frac{3}{3}/2005$

Stephen D. Gillies, Ph.D.

President

EMD Lexigen Research Center Corp.

Bedford Campus

45A Middlesex Turnpike

Billerica, MA 01821